Biological Status before Biological Intervention: A Clinical Framework for Patient Evaluation Prior to Regenerative Longevity Therapies

Miguel G Garber^*

Citation: Garber MG. Biological Status before Biological Intervention: A Clinical Framework for Patient Evaluation Prior to Regenerative Longevity Therapies. J Stem Cell Res. 7(3):1-08.

Received: August 17, 2026 | Published: September 10, 2026

Copyright^© 2026 by Garber M. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

DOI: https://doi.org/10.52793/JSCR.2026.7(3)-97

Abstract

Regenerative interventions should be preceded by a multidomain assessment of biological status, disease burden, physiological reserve, and modifiable carters of accelerated aging. The purpose of evaluation is risk reduction, treatment prioritization, personalization, and longitudinal outcome measurement. This is scientifically balanced. Biological-age biomarkers may support risk stratification and intervention monitoring, but there remains no universal agreement on how they should be validated for routine clinical decision-making. Functional and physiological measures currently have particularly strong clinical relevance.

Keywords

Regenerativa longevity medicine; Metabolic status; Cell-based therapies

Introduction

Regenerativa longevity medicine is increasingly moving beyond a conventional “treatment-first” paradigm toward a more individualized, phenotype-driven approach to healthspan preservation. Patients increasingly seek stem-cell-derived products, extracellular vesicles/exosomes, peptides, and adjunctive modalities such as hyperbaric oxygen therapy. However, their biological response, risks, and clinical indications remain heterogeneous and depend on the individual’s biological and functional state. Accordingly, the central clinical question should be: What is the patient’s biological and functional phenotype, and which modifiable drivers of decline should be addressed before considering regenerative intervention? This requires assessment beyond chronological age and isolated biomarkers, incorporating metabolic and cardiovascular health, systemic inflammation, organ function, physical performance, nutritional status, and biological resilience. Within this framework, regenerative longevity medicine should focus not on lowering a biological-age score, but on preserving healthspan, functional capacity, tissue resilience, and quality of life. Biological-age measures should therefore be considered complementary surrogate markers rather than primary therapeutic targets, while emerging interventions should be selected according to appropriate indications, available evidence, and a broader preventive and precision-medicine framework.

Biological status as the initial treatment point

Regenerative medicine should begin with an evaluation of the patient's biological status. The central question is not simply “Which regenerative therapy should we use?”, but rather: “What is the patient's biological and functional phenotype, and which factors are limiting the capacity for repair and regeneration?”

A comprehensive biological assessment should therefore characterize the major systems that influence tissue repair, cellular function, and biological resilience.

1. Inflammatory status, assessment of systemic and low-grade chronic inflammation is essential. This include hs-CRP, fibrinogen, CBC-derived inflammatory indices, ferritin, cytokine profiles, and potentially emerging biomarkers such as suPAR. The objective is to identify whether chronic inflammatory signaling may be impairing regenerative responses.
2. Metabolic status, glucose metabolism, insulin sensitivity, body composition, liver and renal function, uric acid, nutritional status, and metabolic syndrome parameters should be evaluated. Metabolic dysfunction can substantially influence mitochondrial function, vascular health, inflammation, and tissue regeneration.
3. Glycemic status, fasting glucose, HbA1c, fasting insulin and, when clinically appropriate, measures of insulin resistance or continuous glucose monitoring can provide a more complete picture than glucose alone.
4. Lipid and cardiovascular status, total cholesterol and LDL-C should be complemented, when appropriate, by ApoB, triglycerides, HDL-C and lipoprotein(a), together with an assessment of blood pressure and overall cardiovascular risk. The objective is to understand the patient's vascular and cardiometabolic environment rather than treating lipid values in isolation.
5. Vascular and microcirculatory status, adequate perfusion and oxygen delivery are fundamental prerequisites for regeneration. Depending on the indication, assessment may include endothelial function, arterial stiffness, peripheral circulation, ankle-brachial index, vascular imaging, and other functional measurements. In selected patients, evaluation of tissue oxygenation may also be relevant.
6. Endocrine and hormonal status, thyroid function, adrenal-related parameters, gonadal hormones and other endocrine axes should be evaluated according to age, sex, symptoms and clinical indication. Hormonal imbalance can influence metabolism, inflammation, muscle mass, bone health, vascular function and regenerative capacity.
7. Stress and neuroendocrine status, chronic psychological and physiological stress can influence autonomic balance, sleep, cortisol signaling, inflammation and metabolic regulation. Evaluation should therefore include sleep quality, autonomic function and clinically appropriate stress-related biomarkers rather than relying exclusively on a single laboratory measurement.
8. Nutritional and micronutrient status, protein intake, body composition and selected micronutrients—including vitamin D, B12, folate, iron status and other parameters when indicated—should be considered. Regeneration requires adequate substrates for cellular proliferation, mitochondrial activity, extracellular matrix synthesis and immune function.
9. Cellular and regenerative status, the evaluation can be expanded toward circulating progenitor-cell populations, cellular senescence-related biomarkers, extracellular vesicle profiles, proteomics, metabolomics or other advanced biological assessments. These approaches may help characterize regenerative potential, although many remain investigational and require standardized interpretation.
10. Biological age and functional phenotype, chronological age alone is an insufficient descriptor of regenerative capacity. Where validated and clinically appropriate, biological-age assessments, organ-specific biomarkers, physical performance, muscle function, cognitive function and other functional measures can provide additional information about biological resilience.

The purpose of this evaluation is to identify the dominant biological bottlenecks affecting the patient's capacity to respond.

Prehabilitation with biological optimization before regeneration

In regenerative medicine, the first intervention is not the regenerative product itself. Evaluate the metabolic dysfunction, chronic low-grade inflammation, endothelial dysfunction, poor nutritional status, sleep disturbance, hormonal imbalance, or impaired physical conditioning, the biological environment may be the primary limitation to regenerative intervention. Therefore, before administering cells, extracellular vesicles, PRP, peptides, or other regenerative interventions, we should ask: Is this patient biologically prepared to respond to a regenerative stimulus?

Prehabilitation and biological optimization, is the process of identifying and correcting the modifiable biological barriers that may impair tissue repair.

The rationale is straightforward, regeneration requires an appropriate biological context. Cells need adequate oxygen and nutrient delivery; tissues require sufficient vascularization and mitochondrial function; extracellular matrix remodeling requires appropriate signaling; and the immune system must be capable of coordinating repair rather than maintaining persistent inflammatory signaling.

Consequently, the objective is not simply to add regenerative signals, but to make the patient's biology receptive to those signals.

You can call this concept “host optimization before regeneration.

Responsible use of advanced regenerative therapies

The clinical application of advanced regenerative therapies should follow a cautious, evidence-based, and patient-centered framework. Cell-based therapies, extracellular vesicles, exosome-based products, and peptide-based interventions remain heterogeneous with respect to their biological composition, manufacturing processes, characterization, potency, dosing, route of administration, clinical indications, and level of supporting evidence. Therefore, therapeutic decisions should be based on the specific characteristics of the intervention and the individual patient's biological and clinical phenotype rather than on the therapeutic category alone.

A responsible clinical approach should include:

1. Appropriate patient selection and risk stratification, based on clinical history, biological status, comorbidities, and the specific indication.
2. Product characterization and traceability, including documentation of source, manufacturing process, quality-control parameters, storage, handling, and batch identification, whenever applicable.
3. Comprehensive informed consent, clearly communicating the established evidence, uncertainties, potential risks, alternative treatments, and the investigational nature of interventions when applicable.
4. Predefined clinical and biological endpoints, allowing treatment effects to be evaluated objectively and distinguishing them from placebo effects, regression to the mean, natural disease variation, or improvements resulting from lifestyle, exercise, weight reduction, medication optimization, or other concurrent interventions.
5. Systematic safety surveillance and adverse-event reporting, with appropriate follow-up according to the intervention and clinical indication.
6. Longitudinal assessment of outcomes, incorporating both patient-reported outcomes and objective functional, clinical, and biological measures whenever appropriate.

Importantly, regenerative therapies should be considered adjunctive or investigational approaches when evidence is insufficient and should not replace established guideline-based prevention and treatment of cardiovascular, metabolic, hepatic, renal, inflammatory, neurological, or other chronic diseases.

Conclusion

Regenerative longevity medicine should move from an intervention-centred model toward a phenotype-guided, biology-first approach. The objective should be the patient's biological and functional phenotype and identify the mechanisms that may be driving accelerated aging, loss of resilience, and impaired tissue repair.

A comprehensive baseline assessment to identify modifiable biological barriers and defining individualized therapeutic priorities. For many patients, the first regenerative intervention should therefore be prehabilitation: correction and optimization of the biological environment before, or in parallel with, more advanced regenerative interventions. Improving metabolic control, reducing chronic inflammatory burden, optimizing vascular function, correcting nutritional deficiencies, improving sleep and physical conditioning, and addressing other modifiable factors may increase the biological readiness of tissues to respond to regenerative signals.

Only after this biological context has been established should interventions such as cell-based therapies, extracellular vesicles, PRP, peptides, or other bioactive strategies be considered according to the specific indication, available evidence, patient risk profile, and appropriate regulatory framework. Their use should remain evidence-based, traceable, and accompanied by informed consent, predefined outcomes, and systematic safety monitoring.

Ultimately, regenerative longevity medicine should be understood as a dynamic process of biological assessment, optimization, targeted intervention, and longitudinal reassessment.

The fundamental clinical question is therefore “What is this patient's biological and functional phenotype, what is limiting their capacity for repair, and which modifiable drivers should be corrected before we attempt to regenerate?”. This shift may provide a more   scientifically rigorous framework for personalized regenerative and longevity medicine.

References

1. Moqri M, Herzog C, Poganik JR, Ying K, Justice JN, et at. (2024) Validation of biomarkers of aging. Nat Med. 30(2):360-72.
2. Furrer R, Handschin C. (2025) Biomarkers of aging: from molecules and surrogates to physiology and function. Physiol Rev. 105(3):1609-94.
3. WHO: Integrated care for older people (‎ICOPE)‎: guidance for person-centred assessment and pathways in primary care, 2nd ed, 22 September 2025| Handbook
4. Van Delen M, Derdelinckx J, Wouters K, Nelissen I, Cools N, et al. (2024)  A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy. J Extracell Vesicles. 13(7):e12458.
5. Zhang T, Zhang L, Ma X, Song W. (2025) The tiny giants of regeneration: MSC-derived extracellular vesicles as next-generation therapeutics. Front Cell Dev Biol. 13:1612589.
6. Perri G, French C, Agostinis-Sobrinho C, Anand A, Antarianto R D, et al. (2025) An expert consensus statement on biomarkers of ageing for use in intervention studies. The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 80(5), Article 80(5):glae297.
7. Si Y, Hanewald K, Chen S, Li B, Batemana H, et al. (2023) Life-course inequalities in intrinsic capacity and healthy ageing. 1;101(5):307-16C.
8. Yusri K, Kumar S, Fong S, Gruber J, Sorrentino V, et al. (20256y) Towards Healthy Longevity: Comprehensive Insights from Molecular Targets and Biomarkers to Biological Clocks. Int J Mol Sci. 25(12):6793.
9. Heras E, Missé J, Ulloa E, Ballester G, Anglada M, et al. (2025) Implementation and validation of the WHO ICOPE framework in andorra: a nationwide pilot study. JAR Life. 2025 Dec 31;15:100033.
10. Biomarkers of Aging Consortium. Validation of biomarkers of aging. Nature Medicine. 202. https://doi.org/10.1038/s41591-023-02784-9
11. Perri, G., French, C., Agostinis-Sobrinho, C., Anand, A., Antarianto, R. D., Arai, Y., Baur, J. A., Cauli, O., Clivaz-Duc, M., Colloca, G., Demetriades, C., de Lucia, C., Di Gessa, G., Diniz, B. S., Dotchin, C. L., Eaglestone, G., Elliott, B. T., Espeland, M. A., Ferrucci, L., Fisher, J., ... Shannon, O. M. (2024). An expert consensus statement on biomarkers of ageing for use in intervention studies. The Journals of Geronto
12. Rajendran RL, Mahajan AA, Muthu S, Rajappan Chandra SK, Gangadaran P, et al. (2026)( Global Research Trends in Extracellular Vesicle-Based Therapy for Regenerative Medicine: A Bibliometric Analysis (2014-2024). Bioengineering (Basel). 13(2):247.
13. Lener T, Gimona M, Aigner L, Börger V, Buzas E, et al. (2015) Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles. 31;4:30087